Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development

Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC patients, sorafenib—a multikinase inhibitor drug—has been reported to exert anti-fibrotic activity. However, incomplete inhibition of RAF activity by sorafenib may also induce paradoxical activation of the mitogen-act...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Yun-Chieh, Liu, Ya-Chi, Chao, Po-Han, Chang, Chih-Chun, Jin, Pei-Ru, Lin, Ts-Ting, Lin, Ja-An, Cheng, Hui-Teng, Wang, Jane, Lai, Charles P., Chen, Ling-Hsuan, Wu, Anthony Y., Ho, Ting-Lun, Chiang, Tsaiyu, Gao, Dong-Yu, Duda, Dan G., Chen, Yunching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817100/
https://www.ncbi.nlm.nih.gov/pubmed/29463989
http://dx.doi.org/10.7150/thno.21168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817100/
https://www.ncbi.nlm.nih.gov/pubmed/29463989
http://dx.doi.org/10.7150/thno.21168

Ejemplares similares